Cellectis (CLLS): 2017 Could Be The Transformative Year - Oppenheimer

September 14, 2016 7:47 AM EDT
Get Alerts CLLS Hot Sheet
Price: $19.00 -0.31%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade CLLS Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Oppenheimer analyst Michelle Gilson, reiterated her Outperform rating on shares of Cellectis (NASDAQ: CLLS) after the company Cellectis reported 2Q16 results that included €270M (US$303M) in cash, enough to to fund anticipated operations through YE2018. The anlalyst is focused UCART123 trials in AML and BPDCN which have YE2016/early-2017 trial starts, and initial data expected 2H17.

The analyst believes UCART19 (partnered with Servier/Pfizer) data from compassionate use program will be presented at ASH. Checks suggest multiple patients have been treated under compassionate use and early clinical data from the Phase 1 clinical study of UCART19 in pediatric B-ALL patients could also be presented at ASH, at the discretion of partners.

No change to the $65 PT.

price target of $65.00

For an analyst ratings summary and ratings history on Cellectis click here. For more ratings news on Cellectis click here.

Shares of Cellectis closed at $24.76 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, FDA

Add Your Comment